Raymond James analyst Michael Freeman downgraded Avidity Biosciences (NASDAQ: RNA) from Outperform to Strong Buy.The analyst comments: "Avidity's neuromuscular assets ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE